This trial is investigating whether the Kardia Mobile monitoring device is a superior strategy for diagnosing Atrial Fibrillation (AF) in comparison to normal ambulatory monitoring with a 24-hour Holter monitor.
1 Primary · 0 Secondary · Reporting Duration: 6 months
220 Total Participants · 2 Treatment Groups
Primary Treatment: Standard of Care · No Placebo Group · N/A
Age 18+ · All Participants · 3 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: